United Neuroscience announced an upcoming presentation on Phase IIa results of its lead clinical product, UB-311, at the 14th International Conference on Alzheimer’s and Parkinson’s Diseases in Lisbon, Portugal, from March 26-31, 2019.
March 28, 2019
· 2 min read